BACKGROUND: Staphylococcus aureus is a leading cause of bacteremia, yet there remains a significant knowledge gap in the identification of relevant biomarkers that predict clinical outcomes. Heterogeneity in the host response to invasive S. aureus infection suggests that specific biomarker signatures could be utilized to differentiate patients prone to severe disease, thereby facilitating earlier implementation of more aggressive therapies. METHODS: To further elucidate the inflammatory correlates of poor clinical outcomes in patients with S. aureus bacteremia, we evaluated the association between a panel of blood proteins at initial presentation of bacteremia and disease severity outcomes using 2 cohorts of patients with S. aureus bacteremia (n = 32 and n = 124). RESULTS: We identified 13 candidate proteins that were correlated with mortality and persistent bacteremia. Prognostic modeling identified interleukin (IL)-8 and CCL2 as the strongest individual predictors of mortality, with the combination of these biomarkers classifying fatal outcome with 89% sensitivity and 77% specificity (P < .0001). Baseline IL-17A levels were elevated in patients with persistent bacteremia (P < .0001), endovascular (P = .026) and metastatic tissue infections (P = .012). CONCLUSIONS: These results demonstrate the potential utility of selected biomarkers to distinguish patients with the highest risk for treatment failure and bacteremia-related complications, providing a valuable tool for clinicians in the management of S. aureus bacteremia. Additionally, these biomarkers could identify patients with the greatest potential to benefit from novel therapies in clinical trials.
BACKGROUND:Staphylococcus aureus is a leading cause of bacteremia, yet there remains a significant knowledge gap in the identification of relevant biomarkers that predict clinical outcomes. Heterogeneity in the host response to invasive S. aureus infection suggests that specific biomarker signatures could be utilized to differentiate patients prone to severe disease, thereby facilitating earlier implementation of more aggressive therapies. METHODS: To further elucidate the inflammatory correlates of poor clinical outcomes in patients with S. aureus bacteremia, we evaluated the association between a panel of blood proteins at initial presentation of bacteremia and disease severity outcomes using 2 cohorts of patients with S. aureus bacteremia (n = 32 and n = 124). RESULTS: We identified 13 candidate proteins that were correlated with mortality and persistent bacteremia. Prognostic modeling identified interleukin (IL)-8 and CCL2 as the strongest individual predictors of mortality, with the combination of these biomarkers classifying fatal outcome with 89% sensitivity and 77% specificity (P < .0001). Baseline IL-17A levels were elevated in patients with persistent bacteremia (P < .0001), endovascular (P = .026) and metastatic tissue infections (P = .012). CONCLUSIONS: These results demonstrate the potential utility of selected biomarkers to distinguish patients with the highest risk for treatment failure and bacteremia-related complications, providing a valuable tool for clinicians in the management of S. aureus bacteremia. Additionally, these biomarkers could identify patients with the greatest potential to benefit from novel therapies in clinical trials.
Authors: Warren E Rose; Jens C Eickhoff; Sanjay K Shukla; Madhulatha Pantrangi; Suzan Rooijakkers; Sara E Cosgrove; Victor Nizet; George Sakoulas Journal: J Infect Dis Date: 2012-09-10 Impact factor: 5.226
Authors: Belinda M Maher; Michelle E Mulcahy; Alison G Murphy; Mieszko Wilk; Kate M O'Keeffe; Joan A Geoghegan; Ed C Lavelle; Rachel M McLoughlin Journal: Infect Immun Date: 2013-09-30 Impact factor: 3.441
Authors: Cecilia F Volk; Sarah Burgdorf; Graham Edwardson; Victor Nizet; George Sakoulas; Warren E Rose Journal: Clin Infect Dis Date: 2020-06-10 Impact factor: 9.079
Authors: Gowrishankar Muthukrishnan; Sandeep Soin; Christopher A Beck; Alex Grier; James D Brodell; Charles C Lee; Cheryl L Ackert-Bicknell; Frances Eun-Hyung Lee; Edward M Schwarz; John L Daiss Journal: Immunohorizons Date: 2020-06-22
Authors: Vidmantas Petraitis; Ruta Petraitiene; Povilas Kavaliauskas; Ethan Naing; Andrew Garcia; Christina Sutherland; Aki Yoneda Kau; Nicholas Goldner; Christopher Bulow; David P Nicolau; Thomas J Walsh Journal: Antimicrob Agents Chemother Date: 2021-08-30 Impact factor: 5.191
Authors: Emily M Eichenberger; Felicia Ruffin; Batu Sharma-Kuinkel; Michael Dagher; Lawrence Park; Celia Kohler; Matthew R Sinclair; Stacey A Maskarinec; Vance G Fowler Journal: Transpl Infect Dis Date: 2021-12-16 Impact factor: 2.228
Authors: Emily M Eichenberger; Felicia Ruffin; Michael Dagher; Reginald Lerebours; Sin-Ho Jung; Batu Sharma-Kuinkel; Andrew N Macintyre; Joshua T Thaden; Matthew Sinclair; Lauren Hale; Celia Kohler; Scott M Palmer; Barbara D Alexander; Vance G Fowler; Stacey A Maskarinec Journal: Am J Transplant Date: 2020-11-20 Impact factor: 9.369
Authors: Alessander O Guimaraes; Johnny Gutierrez; Stacey A Maskarinec; Yi Cao; Kyu Hong; Felicia Ruffin; Montserrat Carrasco-Triguero; Melicent C Peck; Vance G Fowler; Amos Baruch; Carrie M Rosenberger Journal: Open Forum Infect Dis Date: 2019-03-15 Impact factor: 3.835
Authors: Nagendra N Mishra; Arnold S Bayer; Sarah L Baines; Ashleigh S Hayes; Benjamin P Howden; Christian K Lapitan; Cassandra Lew; Warren E Rose Journal: Microorganisms Date: 2021-05-11
Authors: Felix Mba Medie; Batu K Sharma-Kuinkel; Felicia Ruffin; Liana C Chan; Maura Rossetti; Yu-Ling Chang; Lawrence P Park; Arnold S Bayer; Scott G Filler; Richard Ahn; Elaine F Reed; David Gjertson; Michael R Yeaman; Vance G Fowler Journal: Proc Natl Acad Sci U S A Date: 2019-09-16 Impact factor: 11.205